Inovalon Holdings, Inc. (INOV) Shares Bought by Oppenheimer Asset Management Inc.
Oppenheimer Asset Management Inc. grew its stake in shares of Inovalon Holdings, Inc. (NASDAQ:INOV) by 3.4% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 104,171 shares of the technology company’s stock after buying an additional 3,388 shares during the period. Oppenheimer Asset Management Inc. owned approximately 0.07% of Inovalon worth $1,776,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently made changes to their positions in INOV. Dimensional Fund Advisors LP acquired a new position in shares of Inovalon during the first quarter valued at about $650,000. Bank of Montreal Can increased its stake in Inovalon by 0.4% in the second quarter. Bank of Montreal Can now owns 14,006 shares of the technology company’s stock valued at $184,000 after acquiring an additional 61 shares during the period. Aperio Group LLC increased its stake in Inovalon by 17.8% in the second quarter. Aperio Group LLC now owns 39,375 shares of the technology company’s stock valued at $518,000 after acquiring an additional 5,949 shares during the period. Bessemer Group Inc. increased its stake in Inovalon by 4.9% in the second quarter. Bessemer Group Inc. now owns 14,316 shares of the technology company’s stock valued at $189,000 after acquiring an additional 666 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its stake in Inovalon by 93.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 290,293 shares of the technology company’s stock valued at $3,818,000 after acquiring an additional 140,566 shares during the period. 28.09% of the stock is owned by institutional investors and hedge funds.
In other Inovalon news, President Robert A. Wychulis sold 85,828 shares of the company’s stock in a transaction dated Tuesday, December 5th. The shares were sold at an average price of $15.54, for a total transaction of $1,333,767.12. Following the sale, the president now directly owns 466,286 shares of the company’s stock, valued at $7,246,084.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Shauna L. Vernal sold 5,908 shares of the company’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $16.01, for a total transaction of $94,587.08. Following the sale, the insider now directly owns 47,309 shares in the company, valued at $757,417.09. The disclosure for this sale can be found here. 48.28% of the stock is currently owned by corporate insiders.
Shares of Inovalon Holdings, Inc. (NASDAQ INOV) opened at $14.90 on Wednesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 5.62 and a current ratio of 5.62. The firm has a market cap of $2,180.79, a PE ratio of 71.19, a price-to-earnings-growth ratio of 4.38 and a beta of 1.24. Inovalon Holdings, Inc. has a 52 week low of $8.60 and a 52 week high of $17.80.
Inovalon (NASDAQ:INOV) last issued its quarterly earnings data on Wednesday, November 1st. The technology company reported $0.09 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.08 by $0.01. The firm had revenue of $115.90 million for the quarter, compared to analysts’ expectations of $114.79 million. Inovalon had a net margin of 4.07% and a return on equity of 4.63%. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.10 earnings per share. sell-side analysts predict that Inovalon Holdings, Inc. will post 0.24 EPS for the current fiscal year.
Inovalon Company Profile
Inovalon Holdings, Inc (Inovalon) is a technology company. The Company provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models to the healthcare industry. Leveraging large-scale data interconnectivity capabilities, unparalleled proprietary data sets, advanced analytics, data-driven intervention systems, and subject matter expertise, Inovalon enables the assessment and improvement of clinical and quality outcomes and financial performance across the healthcare ecosystem.
Want to see what other hedge funds are holding INOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inovalon Holdings, Inc. (NASDAQ:INOV).
Receive News & Ratings for Inovalon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalon and related companies with MarketBeat.com's FREE daily email newsletter.